Dr. Ashwin Pachaatt Vinod

2.7K posts

Dr. Ashwin Pachaatt Vinod banner
Dr. Ashwin Pachaatt Vinod

Dr. Ashwin Pachaatt Vinod

@pachaatt

Liver specialist. Alumnus Dept. of Hepatology-PGIMER Chandigarh/ Dept. of Medicine AIIMS New Delhi/ AIIMS Raipur.

Katılım Temmuz 2021
1.1K Takip Edilen974 Takipçiler
Sabitlenmiş Tweet
Dr. Ashwin Pachaatt Vinod
A dream that began years ago has finally come true — Dr. Ashwin P Vinod, MBBS, MD (Medicine), DM (Hepatology) it is! Endless gratitude to Dept. of Hepatology, PGIMER & its incredible faculty for shaping my journey. Thank you all for being part of this dream. @HepatologyPGI
Dr. Ashwin Pachaatt Vinod tweet mediaDr. Ashwin Pachaatt Vinod tweet mediaDr. Ashwin Pachaatt Vinod tweet media
Dr. Ashwin Pachaatt Vinod@pachaatt

6 mon back, I made this doodle, took a print-out and stuck it on the ceiling just above my bed. Today I am one step closer to that dream. Rank 1, Hepatology INI SS. Cheers to 3 years of residency @ PGI Chandigarh, the Mecca of Hepatology in India. @HepatologyPGI #Hepatology

English
5
2
83
6.3K
Dr. Ashwin Pachaatt Vinod retweetledi
Samuel Hume
Samuel Hume@DrSamuelBHume·
The rollout of Lenacapavir, Gilead's twice-yearly HIV-preventative with up to 100% efficacy in trials, is moving forward It's reached 9 countries so far, with 12 more planned – aiming to access 3 million people by 2028
Samuel Hume tweet media
Samuel Hume@DrSamuelBHume

Prevention beats cure, which is why it's so exciting that Lenacapavir, a twice-yearly HIV preventative, just got approved for the first time (by the FDA) Why is it such a big deal? When trialled (in women in South Africa and Uganda) there were 0 HIV infections 🧵

English
2
23
103
9.3K
Dr. Ashwin Pachaatt Vinod retweetledi
Scott Isaacs
Scott Isaacs@scottisaacsmd·
The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. cell.com/cell-metabolis…
Scott Isaacs tweet media
English
4
52
179
8K
Dr. Ashwin Pachaatt Vinod retweetledi
Michael Morelli
Michael Morelli@morellifit·
A massive Nature study of 27,885 GLP-1 users just dropped some major news about Ozempic and tirzepatide. Your DNA determines how much weight you lose and how bad the side effects hit. 1 in 3 people see minimal results, and now we know why: (1/9)
Michael Morelli tweet media
English
61
450
2.3K
622.5K
Dr. Ashwin Pachaatt Vinod retweetledi
Keith Siau
Keith Siau@drkeithsiau·
A reminder that in the HALT-IT trial, tranexamic acid did not ⬇️ mortality or bleeding events, but ⬆️ venous thromboembolic events (x2️⃣). Please stop giving TXA for GI bleeding. Doesn’t matter if it’s upper or lower 🩸- doesn’t work but can cause harm ⛔️ thelancet.com/journals/lance…
Keith Siau tweet media
English
11
207
513
0
Dr. Ashwin Pachaatt Vinod retweetledi
Arndt Vogel
Arndt Vogel@ArndtVogel·
Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in BCLC A HCC and high risk of recurrence @HEP_Journal doi.org/10.1097/HEP.00… 🔎🇫🇷43 pts, NIVOLEP trial 👉ORR 25% after Nivo 👉2yrs OS rate 75% 🧐Not sure whether there is a future for IRI in HCC, but interesting data @EASLedu @myESMO @ILCAnews
Arndt Vogel tweet media
English
4
19
43
3.5K
Dr. Ashwin Pachaatt Vinod retweetledi
Pyrls
Pyrls@PyrlsApp·
FDA Approves FOUNDAYO (orforglipron), an Oral GLP-1 Receptor Agonist, for Weight Loss
Pyrls tweet media
English
0
6
11
913
Dr. Ashwin Pachaatt Vinod retweetledi
Anuraag Jena
Anuraag Jena@DrAnuraagJ·
This slide by Dr Patrick Kamath Which happiness level are you in ?
Anuraag Jena tweet media
English
0
8
24
900
Dr. Ashwin Pachaatt Vinod retweetledi
HEPATOLOGY Journal
HEPATOLOGY Journal@HEP_Journal·
Review Finite nucleos(t)ide analog therapy for functional cure in HBeAg-negative chronic hepatitis B: Recent development in the paradigm shift Liaw et al. #LiverX shorturl.at/Q0y39
HEPATOLOGY Journal tweet media
English
0
3
3
475
Dr. Ashwin Pachaatt Vinod retweetledi
AASLD
AASLD@AASLDtweets·
As the role of #GLP1 therapies in #MASLD continues to grow, clinicians need clear guidance. A new Practice Guidance update in @HEP_Journal provides evidence-based recommendations on using semaglutide therapy for MASH, including patient selection, comorbidity management, and monitoring strategies. 📗 View the update: bit.ly/4s4QM6A
AASLD tweet media
English
1
28
61
3.8K
Dr. Ashwin Pachaatt Vinod retweetledi
𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊
Surviving Sepsis 2026 is here & it's even more loony tunes than I was expecting. They're promoting pre-hospital ABX & preemptive broad-spectrum IV antibiotics for intubated patients. This insane fever dream is an antimicrobial stewardship nightmare. Embarrassment for SCCM.
𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 tweet media
English
37
123
651
125.5K